Adherence to highly active antiretroviral therapy in depressed patients with HIV/AIDS attendinga Nigerian university teaching hospital clinic

African Journal of Psychiatry (South Africa)

Volumn 13, Issue 4, 2010, Pages 275-279

  Olisah, V O ^a   Baiyewu, O ^b   Sheikh, T L ^a  

^a AHMADU BELLO UNIVERSITY   (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Depressive disorder; Highly active antiretroviral therapy; HIV infection; Medication adherence

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NIGERIA; OUTPATIENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREVALENCE; QUESTIONNAIRE; TEACHING HOSPITAL;

EID: 78049434372     PISSN: 19948220     EISSN: None     Source Type: Journal    
DOI: 10.4314/ajpsy.v13i4.61876     Document Type: Article

References (37)

1. UNAIDS/WHO report on Global HIV/AIDS statistics. November 2006.
2. HIV/Syphilis sentinel seroprevalence survey in Nigeria. Technical Report 1999/2005.
3. Chen LF, Hoy J, Lewin SR. Ten years of Highly Active Antiretroviral Therapy for HIV infection. MJA 2007; 186(3): 146-51.
4. Descamps D, Flandre P, Calvez V, Pentavin G, Meiffredy V, Collin G et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of Induction-Maintainance Therapy. JAMA 2000; 283: 205-11.
5. APA. Practice guidelines for the treatment of patients with HIV/AIDS. American Psychiatric Association 2000. www.psych.org.
6. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-66.
7. Demasi RA, Graham MN, Tolson JM, Pham SV, Capuano GA, Fisher RL et al. Correlation between self reported adherence to highly active antiretroviral therapy and virologic outcome. Adv Ther 2001; 18(4): 163-73.
8. Gibb DM, Goodall RL, Guicomet V, Mc Gee L, Compagnucci A, Lyall H, Paediatric European Network for treatment of AIDS Steering Committee. Adherence to prescribed antiretroviral therapy in HIV infected children in the PENTA 5 trial. Pediatr Infect Dis 2003; 22: 56-62.
9. Donenberg GR, Pao M. Youths and HIV/AIDS: Psychiatry's role in a changing epidemic. J Am Acad Child Adolesc Psychiatry 2005; 44(8): 728-47.
10. Murray LK, Semrau K, McCurley E, Thea DM, Scott N, Mwiya M et al. Barriers to acceptance and adherence to antiretroviral therapy in urban Zambian women: a qualitative study. AIDS Care. 2009; 21 (1):78-86.
11. Byakika-Tusiime J, Crane J, Oyugi JH, Ragland K, Kawuma A, Musoke P et al. Longitudinal antiretroviral adherence in HIV+ve Ugandan parents and their children initiating HAART in the MTCT-Plus Family Treatment Model: role of depression in declining adherence over time. AIDS Behav. 2009 Mar 20. [Epub ahead of print] PubMed PMID: 19301113.
12. Liu H, Miller LG, Hays RD, Ogling CE, Wu T, Wenger NS et al. Repeated measures longitudinal analysis of HIV virologic response as a function of percentage adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006; 41(3): 315-22.
13. Yakassai BA. Neuropsychiatric complications of HIV/AIDS. Ann Afr Med 2004; 3(2): 63-5.
14. McDaniel SJ, Campos PE, Purcell DW, Farber EW, Bondurant A, Donovan JE et al. A national, randomized survey of HIV/AIDS attitudes and knowledge among Psychiatrists-in-training. Acad Psychiatry 1998; 22: 107-16.
15. HIV clinical guidelines for the primary care practitioner. Mental Health Care for people with HIV infection. Published by the AIDS Institute, New York State Department of Health, 2000. p 2.
16. Elliot AJ, Roy Byrne PP. Major depressive disorder and HIV-1 infection. Semin Clin Neuropsychiatry 1998; 3:137-50.
17. Olley BO, Gxamza F, Seedat S, Reuter H, Stein DJ. Psychiatric morbidity in recently diagnosed HIV patients South Africa. S Afr Medical Research Council Publication; AIDS Bulletin April 2003; 12 (1): 12-16.
18. Boardman J, Petrushkin H, Ovuga E. Psychiatric disorders in HIV positive individuals in urban Uganda. Br J Psychiatry 2005; 29: 455-58.
19. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London SA et al. The estimated prevalence of psychiatric disorders, drug use and dependence among people with HIV disease in the United States. Arch Gen Psychiatry 2001; 58: 721-28.
20. Ciesla MA, Robert JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158, 5: 725-30.
21. Steven MA, Kilbourne AM, Gifford AL, Burnam MA, Turner B et al. Underdiagnosis of depression in HIV. J Gen Intern Med 2003; 18(6): 450-60.
22. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV positive men. J Clin Psychiatry 1998; 59: 217-24.
23. Rabkin JG, Goetz RR. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV sero-positive women. AIDS J 2002; 30: 401-9.
24. Phyllips J, Gettes D, Douglas S, Bauser R, Evans D. Sleep disturbance and depression as barriers to adherence. Am J Psychiatry 2002; 14(3): 273-80.
25. Dimatteo MR, Lepper HS, Croghan TW. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-07.
26. Mugavero M, Ostermann J, Whetten K, Leserman J, Swartz M, Stangl D et al.Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS 2006; 20(6): 418-28.
27. Rabkin JG. HIV and depression: 2008 review and update. Curr HIV/AIDS Rep. 2008 5(4): 163-71.
28. Cook J. Depressive symptoms increase AIDS-related death. Am J Public Health 2004; 150(10): 85-94.
29. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
30. Ambebir A, Woldemicheal K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIVinfected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008; 30(8): 265.
31. Watt MH, Maman S, Earp JA, Eng E, Setel PW, Golin CE et al. "It's all the time in my mind" : Facilitators of adherence to antiretroviral therapy in a Tanzanian setting. Soc Sci Med. 2009 Mar 26. [Epub ahead of print] PubMed PMID: 19328609.
32. Boroffka A, Olatawura M.O. Community Psychiatry in Nigeria: the current status. Int J of Soc Psychiatry 1976; 23: 1154-58.
33. Comstock DW, Helsing KJ. Symptoms of depression in two communities. J Psychol Med 1976; 551-63.
34. World Health Organization: Research Diagnostic Criteria of International Classification of Diseases 10th edition. WHO Geneva, 1993.
35. Morrison MF, Petitto JM, Ten-Have T, Gettes DR, Chiappini MS. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002; 159: 789-796.
36. Murphy DA, Moussa S, Durako SJ, Moscicki A, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus infected adolescents. Arch Pediatr Adolesc Med 2003; 157: 249-55.
37. 'Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurol 2002; 59: 1944-1950.